ScinoPharm Taiwan Ltd - Asset Resilience Ratio
ScinoPharm Taiwan Ltd (1789) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 1789 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how ScinoPharm Taiwan Ltd's Asset Resilience Ratio has changed over time. See ScinoPharm Taiwan Ltd (1789) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ScinoPharm Taiwan Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 1789 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$90.00K | 0.0% |
| Total Liquid Assets | NT$90.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ScinoPharm Taiwan Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ScinoPharm Taiwan Ltd Industry Peers by Asset Resilience Ratio
Compare ScinoPharm Taiwan Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for ScinoPharm Taiwan Ltd (2007–2025)
The table below shows the annual Asset Resilience Ratio data for ScinoPharm Taiwan Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.00% | NT$90.00K ≈ $2.84K |
NT$11.86 Billion ≈ $373.58 Million |
-0.07pp |
| 2023-12-31 | 0.07% | NT$8.30 Million ≈ $261.62K |
NT$11.72 Billion ≈ $369.29 Million |
-0.36pp |
| 2022-12-31 | 0.43% | NT$51.13 Million ≈ $1.61 Million |
NT$11.91 Billion ≈ $375.27 Million |
0.00pp |
| 2021-12-31 | 0.43% | NT$50.71 Million ≈ $1.60 Million |
NT$11.69 Billion ≈ $368.34 Million |
+0.14pp |
| 2020-12-31 | 0.29% | NT$34.31 Million ≈ $1.08 Million |
NT$11.85 Billion ≈ $373.24 Million |
-1.21pp |
| 2019-12-31 | 1.50% | NT$175.14 Million ≈ $5.52 Million |
NT$11.67 Billion ≈ $367.81 Million |
+0.08pp |
| 2018-12-31 | 1.42% | NT$179.02 Million ≈ $5.64 Million |
NT$12.56 Billion ≈ $395.81 Million |
-2.06pp |
| 2017-12-31 | 3.49% | NT$443.26 Million ≈ $13.97 Million |
NT$12.70 Billion ≈ $400.16 Million |
+0.23pp |
| 2016-12-31 | 3.26% | NT$417.00 Million ≈ $13.14 Million |
NT$12.78 Billion ≈ $402.73 Million |
+0.94pp |
| 2015-12-31 | 2.33% | NT$284.22 Million ≈ $8.95 Million |
NT$12.22 Billion ≈ $385.05 Million |
+5.66pp |
| 2014-12-31 | -3.34% | NT$-379.36 Million ≈ $-11.95 Million |
NT$11.37 Billion ≈ $358.27 Million |
-3.47pp |
| 2013-12-31 | 0.14% | NT$15.55 Million ≈ $489.97K |
NT$11.48 Billion ≈ $361.82 Million |
+0.13pp |
| 2012-12-31 | 0.00% | NT$473.00K ≈ $14.90K |
NT$10.34 Billion ≈ $325.76 Million |
-0.23pp |
| 2011-12-31 | 0.23% | NT$21.99 Million ≈ $692.90K |
NT$9.48 Billion ≈ $298.68 Million |
+0.08pp |
| 2010-12-31 | 0.15% | NT$10.90 Million ≈ $343.32K |
NT$7.30 Billion ≈ $229.93 Million |
-0.63pp |
| 2009-12-31 | 0.78% | NT$45.60 Million ≈ $1.44 Million |
NT$5.82 Billion ≈ $183.49 Million |
-8.13pp |
| 2008-12-31 | 8.91% | NT$513.60 Million ≈ $16.18 Million |
NT$5.76 Billion ≈ $181.52 Million |
+5.00pp |
| 2007-12-31 | 3.91% | NT$220.49 Million ≈ $6.95 Million |
NT$5.64 Billion ≈ $177.59 Million |
-- |
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more